Scienture Holdings, Inc. · NASDAQ:SCNX
Scienture — TRxADE HEALTH — Investor Presentation (May 2023)
14 slides from Scienture's investor presentation, May 15, 2023
Slide 1: Digitalizing the Retail Pharmacy Experience
@TRADEm f Digitalizing the Retail Pharmacy Experience . | Investor Presentation om March 2023 sonal
Slide 2: Safe Harbor Statement
N Safe Harbor Statement ‘The inrmaton set oth herein contains Frar-ookng statements within the flea scutes nw, nclaing these fab prosions ofthe Private Sect Liigaton Ref Ast of 195, erwarlookng statement incl ll atements at do not reat solely to historia orcurent fic including, bt vot ited ta statem
Slide 3: About TRxADE HEALTH, INC.
About TRxADE HEALTH, INC. TRXADE is a technology-enabled health services platform company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S. + Market Leader: Operates one of the largest technology marketp
Slide 4: Divisions of TRxADE HEALTH
4 Divisions of TRXADE HEALTH Pharmaceutical Marketplaces (With Supporting B2B + Supporting Subsidiaries) 4) Pie slices not representative of revenue mix between subsidiaries Business to Business Robust procurement technology platform that delivers a lower cast and transparent procurement process for
Slide 5: TRxADE Marketplace
TRxXADE Marketplace Our B2B Pharmaceutical Supply Chain Platform U.S. Pharmaceutical Industry? + Projected $685B per year industry size by 2023 and growing; Over 65,000 pharmacy facilities * Approximately 9 out of 10 Americans live within 5 miles of a community pharmacy + Excluding several large nat
Slide 6: TRxADE Marketplace
TRxXADE Marketplace Trxade.com (Distributor Pharmaceutical Supply Chain Platform) Our Marketplace Solution *TRXADE’s exchange platform offers a clear and concise interface that allows over 14,500+ registered members in 50 states to analyze “up to-the-minute” supply & pricing from multiple pharma sup
Slide 7: Selected Operational Metrics
Selected Operational Metrics TRXADE Platform TRXADE Prime Our marketplace has over 72 national and regional The focus of Trxade Prime is to be the pharmaceutical supplier of pharmaceutical suppliers providing over 120,000 branded and _ choice for healthcare organizations of all sizes. Our expertise
Slide 8: Selected Financials
% Selected Financials + High Margin: Revenue from transaction fees on marketplace platform (Credit Card/PayPal model) does not include the drugs value (over $100M annually), hence “tech like margins” + Built-Out Platform: 14,500+ registered members with continued platform development requiring minim
Slide 9: Management
Management Suren Ajarapu, Chairman of the Board and Chief Executive Officer ‘Mr. Aljarapu has served as Chairman of the Board, Chief Executive Officer and Secretary since eur acquisition of Trade Group, Ine, a Nevada corporation ("TRXADE Nevada") (our predecessor company) on January 8, 2024, and as
Slide 10: Key Takeaways
10 Key Takeaways NASDAQ:MEDS TRXADE is a technology-enabled health services platform company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S. A Tech Focused Healthcare Services Company + Market Leader:
Slide 11: Contact Us
i Contact Us TRXADE HEALTH, INC. 2420 Brunello Trace Lutz , FL 34558 (800) 261-0281 www.trxadehealth.com @TRADE
Slide 12: Appendix: Consolidated Balance Sheet
ee Rees Appendix: Consolidated Balance Sheet (Unaudited) mar a
Slide 13: Appendix: Consolidated Statements of Operations
Appendix: Consolidated Statements of Operations. Unaudited) ‘TRxADE HEALTH, INC. Consolidied Statement of Operations costo sales Coes Prot ‘Operating Expenses: ‘Wage an saiay expense Profession fos Accom a egal expense Techni expense Genera a anita ‘Total operating expenses Operating Loss "Nonoperat
Slide 14: Appendix: Reconciliation of Net Income to Adj. EBITDA
Appendix: Reconciliation of Net Income to Adj. EBITDA* Reconciliation of Net Income(Loss) attributable to TRKADE HEALTH, Inc., to Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA) and Adjusted EBITDA* ‘Three Months ended March 31, r 2023” 2022 Net loss attributable to TRSADE He